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Abstract
Gliomas account for 5% to 7% of all solid cancers in adults and up to 30% of solid cancers in children; glioblas-
tomas are the most malignant type of glioma and often have dismal prognoses. The alkylating agent temozolomide
provides the greatest chemotherapeutic benefits currently available; however, glioblastoma patients cannot be
cured. Novel drugs that efficiently combat glioblastomas are therefore of great interest. We report here that
JLK1486, an 8-hydroxyquinoline–substituted benzylamine, could represent a novel chemical scaffold to reach this
goal. Indeed, JLK1486 mediated anticancer activity in vivo (through intravenous as well as oral routes of adminis-
trations) in an orthotopic xenograft model and displayed efficiency similar to that of temozolomide. The therapeutic
benefits of JLK1486 seem to relate to its ability to activate various transcription factors (including Myt1, STAT1,
and peroxisome proliferator–activated receptor γ) in glioma cells. These transcription factors are implicated in the
control of glioma cell proliferation, and the resultant global effect of their activation by JLK1486 was cytostatic, not
cytotoxic. Thus, the current study opens the door for the development of novel compounds to combat glioblas-
toma using 8-hydroxyquinoline benzylamine analogs.
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Introduction
Brain cancers account for 10% to 15% of all solid cancers in adults and
up to 30% in children, with gliomas accounting for about half of all
cases in adults and more than two thirds of all cases in children [1–3].
Glioblastomas, which account for approximately 50% of gliomas, are
the most malignant type of glioma and are associated with dismal prog-
noses because of the diffuse, invasive nature of glioblastoma cells [4–7]
as well as their intrinsic resistance to proapoptotic stimuli and thus to
conventional radiotherapy and chemotherapy [5,7,8]. The current
standard of care for glioblastoma patients includes surgery followed
by radiotherapy and concomitant and subsequent (adjuvant) chemo-
therapy with the alkylating drug temozolomide (TMZ) [3,9]. TMZ
increases glioblastoma sensitivity to radiotherapy most effectively
in O6-methylguanine-DNA methyltransferase (MGMT)–negative
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glioblastomas by augmenting the degree of radiation-induced double-
strand DNA damage [3,10]. TMZ-induced DNA damage provokes
sustained proautophagic defenses in glioblastoma cells [11,12], a fea-
ture that ends by late apoptosis [13]. TMZ also displays antiangiogenic
effects in experimental gliomas [14]. However, glioblastoma patients
benefit from TMZ treatment only for a limited period because glio-
blastomas develop resistance to TMZ during treatment [3]. Epigenetic
inactivation of the DNA repair enzymeMGMTseems to be the stron-
gest predictive marker for outcome in TMZ-treated glioblastoma pa-
tients because MGMT can repair methyl-guanosine by demethylating
guanosine, thereby allowing for double-strand break repair [15]. Pro-
longed treatments of experimental gliomas with an astrocytic origin
leads to the emergence of certain levels of resistance to TMZ through
increased expression of GLUT transporters and AKR1C proteins [16],
a feature not observed in experimental gliomas with an oligodendrog-
lial origin [17]. In addition, TMZ treatment must usually be discon-
tinued after 12 to 18 cycles, even in responsive glioblastoma patients,
because of progressive hematologic complications [3,18].
Unfortunately, clinical trials using targeted therapies against vari-
ous receptors or key elements in various signaling pathways have had
minimal success in treating glioblastoma patients [19,20]. It is thus
of great interest to discover and develop novel chemicals aiming to
combat glioblastomas that display intrinsic resistance to apoptosis
and/or escape TMZ therapy during treatment.
The present study characterizes the anticancer activity of JLK1486,
a bis 8-hydroxyquinoline–substituted benzylamine, in various in vitro
and in vivo human glioma models. JLK1486 was selected from a se-
ries of 26 compounds for which we previously showed in vitro anti-
cancer activity [21]. It is well known that several anticancer drugs
used to treat cancer patients (cisplatin, psoralens, mitomycin C) in-
duce interstrand DNA cross-links, and part of this mechanism of ac-
tion occurs through the generation of quinone methides [22]. The
compound under study, JLK1486 (Figure 1A), could mediate its
anticancer activity, at least in vitro, through quinone methide inter-
mediates, which do not react with DNA, but which yield covalent
protein thiol adducts [21]. Whereas quinone methide derivatives have
Figure 1. IC50 in vitro growth-inhibitory concentrations of JLK1486, troglitazone and rosiglitazone in nine cancer cell lines. (A) Chemical
structures of JLK1486 and Cpd30-12, a STAT1 agonist, and of troglitazone and rosiglitazone, two PPARγ agonists. (B) Determination of
the growth-inhibitory effects induced by JLK1486, rosiglitazone and troglitazone in nine cancer cell lines (eight human and one mouse
(B16F10)), including three glioma, two melanoma, and four carcinoma models. Data are presented as mean IC50 values with open, gray,
and black dots corresponding to JLK1486, troglitazone, and rosiglitazone, respectively. Except for B16F10 cell line, the IC50 values ob-
tained for rosiglitazone were higher than 100 μM. IC50 values were obtained from sextuplicate for each experimental condition.
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been widely studied in various types of cancers [22], our previous re-
port [21] seems to be the first in the glioma field. Microarray analysis
further showed that JLK1486 induced the expression of a variety of
stress-related genes responsible for cytotoxic effects in carcinoma cells,
although these genes produced cytostatic effects in glioma cells [21].
The present study, therefore, focuses on the antiglioma effects of
JLK1486 in vitro and in vivo in various glioma models that display
either intrinsic sensitivity or resistance to proapoptotic stimuli. We
used the highly malignant, but apoptosis-sensitive, Hs683 oligoden-
droglioma model [17,23,24] as opposed to the highly malignant and
apoptosis-resistant U373 and T98G astroglioma models [23,25,26].
Materials and Methods
Reagents
Reagents were obtained as follows: TMZ was purchased from
Schering Plough (Brussels, Belgium); troglitazone and rosiglitazone
were from Cayman Chemical (SpiBio, France); cell culture medium
(RPMI), fetal calf serum, glutamine, gentamicin, and penicillin-
streptomycin were from Invitrogen (Merelbeke, Belgium). JLK1486
was synthesized in our laboratory ( J.L. Kraus) as detailed elsewhere [21].
Cell Cultures
We used one mouse and eight human cancer cell lines that were
obtained from the European Collection of Cell Culture (Salisbury,
UK), the American Type Culture Collection (ATCC, Manassas, VA),
and the Deutsche Sammlung von Mikroorganismen und Zellkulturen
(DSMZ, Braunschweig, Germany). The human cancer cell lines in-
cluded the A549 non–small cell lung cancer (DSMZ code ACC107),
the SKMEL-28 melanoma (ATCC code HTB-72), the Hs683 oligo-
dendroglioma (ATCC code HTB-138), the U373 (ATCC code HTB-
17), and T98G (ATCC code CRL-1690) glioblastoma, and the LoVo
colon (ATCC code CCL-229), the PC3 prostate (ATCC code CRL-
1435), and the MCF7 breast (ATCC code HTB-22) cancer cell lines,
whereas the mouse cancer cell line was the B16F10 melanoma line
(ATCC code CRL-6475). The cancer cell lines under study were cul-
tured in RPMI medium supplemented with 10% heat-inactivated fetal
calf serum, 4 mM glutamine, 100 μg/ml gentamicin, and penicillin-
streptomycin (200 U/ml and 200 μg/ml).
Determination of Inhibitory Concentration 50% (IC50 )
In Vitro Growth-Inhibitory Concentrations
The overall growth level of human cancer cell lines was deter-
mined using the colorimetric 3-[4,5-dimethylthiazol-2yl])-diphenyl
tetrazolium bromide (Sigma, Bornem, Belgium) assay as detailed
and validated previously [17,26,27]. The solvent used was DMSO
(highest concentration 0.1%). Spectrophotometric analyses were per-
formed with a Biorad Model 680XR (Biorad, Nazareth, Belgium)
apparatus at 570 nm (with a reference of 630 nm). Each experimen-
tal condition was carried out in sextuplicate. Cells were used during
five passages and came from liquid nitrogen tanks. After five passages,
cells were eliminated, and new cell vials were used. Cell were pas-
saged when they reached 70% to 80% confluence.
Computer-Assisted Phase-Contrast Microscopy
(Quantitative Videomicroscopy)
Direct visualization of JLK1486-induced effects on Hs683 oligo-
dendroglioma morphology was carried out using computer-assisted
phase-contrast microscopy, that is, quantitative videomicroscopy, as
detailed and validated previously [17,26,27]. Hs683 cancer cells
were monitored for 72 hours in the absence (control) or presence
of 100 nM JLK1486 (i.e., the IC50 growth-inhibitory concentration
as calculated by 3-[4,5-dimethylthiazol-2yl])-diphenyl tetrazolium
bromide assay). Movies were built using the obtained time-lapse
image sequences and enabled detailed screening for cell viability to
determine whether the compound under study induced cytostatic
versus cytotoxic effects. All experimental conditions were performed
in triplicate.
Determination of Cell Cycle Kinetics
The cell cycle kinetics of Hs683, T98G, and U373 glioma cells
left untreated or incubated with 100 nM JLK1486 were determined
by flow cytometry analysis using the terminal deoxynucleotidyl trans-
ferase deoxyuridine triphosphate nick-end labeling technique based
on a previously detailed experimental protocol [28]. Each sample was
evaluated in triplicate. Flow cytometry was performed using a Cell Lab
Quanta flow cytometer (Beckman Coulter Analis, Suarlée, Belgium).
Determination of Mitotic Rates
Cells undergoing division exhibit very bright patterns compared
with nondividing cells. On the basis of this observation, we devel-
oped a custom division detector capable of identifying cells under-
going division in time-lapse sequences [29]. This detection method
is based on an automatic event detection completed by an interactive
validation/correction procedure as described previously [29]. The
total number of mitoses was determined in Hs683, T98G, and U373
glioma cells treated for 72 hours with 100 nM JLK1486. Each sam-
ple was evaluated in triplicate.
Determination of Apoptotic Death Features
Apoptotic rates of Hs683, T98G, and U373 glioma cells left
untreated (control) or treated for 72 hours with 100 nM JLK1486
were determined using flow cytometry (terminal deoxynucleotidyl
transferase deoxyuridine triphosphate nick-end labeling technique)
as detailed previously [28]. Briefly, glioma cells (both nonadherent
cells and adherent cells) were harvested, pooled, and fixed with 1%
paraformaldehyde (for 1 hour) and overnight with 70% ethanol (for
15 hours). Then, the cells were processed using the APO-Direct Kit
(BD Pharmingen, Erembodegem, Belgium) according to the manufac-
turer’s instructions. Fluorescence intensity was analyzed immediately
on a Cell Lab Quanta flow cytometer (Beckman Coulter Analis).
Treatment of human PC3 prostate cancer cells with 1 μM narciclasine
for 72 hours was used as a positive control.
Kinase Activity Determination
We originally prepared ProQinase (Freiburg, Germany) with
JLK1486 as a stock solution in 100% DMSO, and aliquots were fur-
ther diluted with water in 96-well microliter plates immediately be-
fore use. For each kinase assay, 5 μl from a 2 × 105 M/10% DMSO
compound solution were transferred into the assay plates. The final vol-
ume of the assay was 50 μl. The final assay concentration of JLK1486
was 100 nM. A radiometric protein kinase assay (33PanQinase Activ-
ity Assay; Table W1) was used to measure the kinase activity of the 256
protein kinases under study as detailed previously [30].
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Transcription Factor Array
Hs683 cells were treated with 100 nM JLK1486. After 12 hours,
cells were scraped into cold PBS buffer, and nuclear extracts were
isolated from these cells using the nuclear extraction kit from Active
Motif (catalog number no. 40010; Rixensart, Belgium). Arrays were
performed using TranSignal protein/DNA arrays (SA Biosciences
[Tebu-Bio], Boechout, Belgium) according to the manufacturer’s in-
structions. In brief, biotin-labeled DNA binding oligonucleotides
(TranSignal probe mix; Panomics [Ozyme; Montigny-Le-Bretonneau,
France]) were incubated with 15 μg of nuclear extract to allow the
formation of protein/DNA (or TF/DNA) complexes. The protein/
DNA complexes were then separated from the free probes using the
provided spin columns. The eluted and labeled probes were hybridized
to the TranSignal Array membrane overnight at 42°C. Eachmembrane
was then incubated with streptavidin–horseradish peroxidase conju-
gate, developed with a substrate solution containing luminol enhancer
and peroxide solution, and then exposed using Hyperfilm ECL (GE
Healthcare, Diegem, Belgium). Scanned films were analyzed using
an Aida image analyzer (RayTest, Straubenhardt, Germany).
Peroxisome Proliferator–Activated Receptor Activation Assay
U373 cells were treated with 100 nM JLK1486 for 4 or 24 hours.
After these incubations, cells were collected and nuclear extracts
were purified according to the manufacturer’s instructions (PPARα,
PPARβ/δ, PPARγ; Complete Transcription Factor Assay Kit; Cayman
Chemical). In brief, cells were detached with trypsin and centrifuged
at 300g for 5 minutes. The pellets were resuspended in an ice-cold
PBS/phosphatase inhibitor solution for 5 minutes. This step was re-
peated once. Extracts were resuspended in ice-cold hypotonic buffer
and incubated for 15 minutes. To break the cytoplasmic membrane,
cells were treated with Nonidet P40 (Sigma-Aldrich). The extracts
were centrifuged and the cytoplasmic fraction was saved for other
applications. The pellet was resuspended in an extraction buffer con-
taining protease inhibitor and incubated with gentle rocking for
30 minutes on ice. Extracts were centrifuged at 14,000g for 10 min-
utes at 4°C. The supernatant contained the nuclear fraction. Nuclear
extracts were loaded in 96-well plates and incubated overnight at 4°C.
The primary antibody (from the PPARα, β/δ, γ; Complete Tran-
scription Factor Assay Kit) was added and incubated for 1 hour
at room temperature. The wells were washed five times, and a goat
antirabbit HRP-conjugated secondary antibody was added and incu-
bated for 1 hour at room temperature. The wells were washed five
times. Developing solution was added for 45 minutes, and absorbance
was measured at 450 nm with a spectrophotometer (Biorad Model
680XR; Biorad).
p21waf /cip1 and STAT1 Activation Assay
Western blot analyses were performed as detailed previously
[14,28,31]. Equal loading was verified by the bright Ponceau red colora-
tion of the membranes, and the integrity and quantity of the extracts
were assessed by tubulin immunoblot analysis. Approximately 20 μg
of extracted proteins (evaluated by the bicinchoninic acid protein
assay; Pierce, Perbio Science, Erembodegem, Belgium) was then loaded
onto a denaturing polyacrylamide gel. The following primary anti-
bodies were used for Western blot analysis: anti-p21 (dilution 1:200;
BD Pharmingen), anti-STAT1 (dilution 1:500; BD Pharmingen),
anti–phospho-STAT1 Y701 (dilution 1:250; BD Pharmingen), and
antitubulin (dilution 1:3000; Abcam, Cambridge, UK). Secondary anti-
bodies were purchased from Pierce (PerbioScience). Western blots were
developed using the Pierce SuperSignal Chemiluminescence System.
Molecular Docking for Peroxisome
Proliferator–Activated Receptors
Receptor and ligand preparation. Peroxisome proliferator–activated
receptor α, β/δ, and γ protein coordinates were obtained from the
RCSB Protein Data Bank, codes 1K7L, 1GWX, and 2PRG respec-
tively. Three-dimensional structures were visualized and modified with
Discovery Studio 2.1 (Accelrys, San Diego, CA) as follows. If dimers
were present, both chains were separated and considered individually.
Water molecules and protein fragments used for crystallization were
removed (if any), incomplete residues were modified with the “Clean
Protein” command from the Protein Reports and Utilities module,
hydrogen atoms were added, and the resulting structures were saved
in the pdb format. PPARγ, which was cocrystallized with rosiglita-
zone, was used as template to identify the binding pocket for docking
experiments. The software used in this study was Vina [32], which
allows side chain flexibility within the receptor during the docking
process. All receptor residues within a 9-Å distance from the ligand
were selected and defined as flexible. The corresponding amino acids
in PPARα and PPARβ/δ were similarly chosen to allow flexibility
and define the docking binding site. The receptor files for Vina ex-
periments were prepared with AutoDock Tools [33] and utilities,
where only polar hydrogen atoms were conserved in the resulting
files that were saved in the pdbqt format. This file format differs from
the pdb one by the presence of atomic charges that are irrelevant with
any scoring function used in this study, thus no specific adjustments
were necessary besides an overall control of the receptor structures.
The ligands were prepared in the pdb format with DS 2.1, and ADT
scripts were used to obtain the corresponding pdbqt files. All ligands
were considered flexible during the docking process.
Selectivity screening. Simulations were first performed with rosi-
glitazone and PPARγ to check the validity of the parameters, but
the obtained docked poses did not correspond to the crystals. Reduc-
tion in the number of flexible residues did not lead to any improve-
ment in the poses, and convergence over several experiments was
never attained. Finally, rosiglitazone was flexibly docked into rigid
PPARγ within a 22.0 × 22.0 × 24.0 Å box centered on the ligand.
In this case, the obtained poses were both consistent with the crystal
structure and were convergent over five independent experiments.
These parameters were then applied to the PPARα and β/δ receptors,
and convergence was also observed in these cases. Troglitazone and
JLK1486 were docked into the three PPARs in five independent ex-
periments to compare their respective affinity for the different iso-
forms. The resulting binding energy for each compound refers to
the mean calculated from the best poses. In each case, the best ligand
poses were identical from one experiment to another, which consti-
tutes the above-mentioned convergence.
Molecular Docking for STAT1 versus STAT3
Receptor and ligand preparation. STAT1 and STAT3 protein co-
ordinates were obtained from the RCSB Protein Data Bank, codes
1BF5 and 1BG1, respectively. Three-dimensional structures were
visualized and modified according to the procedure described for
PPAR, but in this case, the DNA oligomers were removed. Because
Translational Oncology Vol. 4, No. 3, 2011 The Use of Hydroxyquinoline to Combat Gliomas Bruyère et al. 129
the SH2 domain was the intended target, we selected the amide bond
between V631 and G632 as the center of the binding pocket for
docking experiments with STAT1, which correspond to the bond be-
tween V637 and G638 in STAT3. To get a wide binding site, resi-
dues within a 9-Å distance of V631-E632 were selected as flexible for
STAT1, and the corresponding residues within STAT3 were deduced
from the sequence alignment, which resulted in 59 and 58 torsions
for the respective docking sites. To ensure a correct docking process,
the search space was defined to encompass all flexible residues as a
box with dimensions of 27.0 × 23.3 × 24.9 Å. Vina requires two
receptor files when performing flexible docking: one corresponding
to the rigid body of the protein and a second corresponding to the
side chains of the previously selected residues. These files were pre-
pared with AutoDock Tools (ADT) [33]. The ligand files were pre-
pared in a similar manner as described for PPAR docking.
Selectivity screening. We used Cpd30-12 (Figure 1A), which is se-
lective for STAT1 versus STAT3 [34], to verify the ability of JLK1486
to bind STAT1 rather than STAT3. Both putative ligands were docked
into the previously defined active sites in five independent experi-
ments. The resulting binding energy for each compound refers to
the mean calculated from the best poses. In each case, the best ligand
poses were identical from one experiment to another; the obtained
energy differed because of the receptor torsion.
In Vivo Orthotopic Hs683 Xenografting Procedures
Hs683 glioma cells were grafted orthotopically into the brains of
immunocompromised mice as described previously [17,23,24]. In
each experiment, all mice (8-week-old female nu/numice; 21-23 g; Iffa
Credo, Charles Rivers, Arbresle, France) had 100,000 Hs683 cells im-
planted on the same day into the left temporal lobe. Mice were then
treated or not (control) with TMZ (40 mg/kg intravenously [i.v.] vs
80 mg/kg per os) and JLK1486 (10 mg/kg i.v. vs 20 mg/kg per os) three
times per week for 3 weeks starting at day 5 after graft. In vivo toler-
ance of TMZ and JLK1486 was defined as the maximal tolerated dose,
which represents the highest single dose of the compound that can be
administered i.v. or orally to experimental groups of healthy mice dur-
ing a maximum period of 28 days without causing death. These doses
were 80 mg/kg i.v. and greater than 160 mg/kg per os for TMZ and
20 mg/kg i.v. and 40 mg/kg per os for JLK1486. We assayed each com-
pound in each route of administration at its maximal tolerated dose/
2 concentration because we administered the compounds nine times
to Hs683 xenograft-bearing mice. Each experimental group contained
11 mice. Each compound has been diluted in saline (NaCl 0.9%) as a
solvent and 200 μl has been administered to the mice. All in vivo ex-
periments described in the present study were performed under autho-
rization no. LA1230509 of the Animal Ethics Committee of the
Federal Department of Health, Nutritional Safety, and the Environ-
ment (Belgium).
Statistics
Survival analyses were carried out by means of Kaplan-Meier curves
(Statistica software; Statsoft, Tulsa, OK).
Results
IC50 In Vitro Growth-Inhibitory Concentrations
Figure 1B details the IC50 in vitro growth-inhibitory concentrations
of JLK1486 in eight human and one mouse cancer cell lines. JLK1486
displays similar growth-inhibitory effects in glioma (Hs683, U373,
T98G), melanoma (SKMEL28, B16F10), and carcinoma (LoVo,
PC3, MCF7, and A549) cell lines, as well as in cancer cell lines that
display actual sensitivity to proapoptotic stimuli (Hs683, B16F10,
LoVo, PC3, and MCF7) and cancer cell lines that display various
levels of intrinsic resistance to proapoptotic stimuli (U373, T98G,
SKMEL28, and A549). The levels of apoptosis sensitivity of all these
cancer cell lines have been determined in a previous work performed
by our group (data not shown).
Part of the anticancer properties of JLK1486 could relate to
PPARγ activation as detailed below. We, therefore, decided to com-
pare JLK1486-induced growth-inhibitory effects in vitro to those
associated with PPAR agonists, including troglitazone and rosiglita-
zone, whose chemical structures are shown in Figure 1A. The data in
Figure 1B clearly indicate that JLK1486 displays higher growth-
inhibitory effects than troglitazone and rosiglitazone in the nine
cancer cell lines under study. These data thus suggest that PPARγ
activation is not the sole mechanism by which JLK1486 exerts its
antiglioma effects.
JLK1486 Induces Cytostatic, Not Cytotoxic,
Effects in Glioma Cells
Quantitative videomicroscopy analysis showed that 100 nM
JLK1486 impaired Hs683 cell proliferation while inducing no cyto-
toxic effects (Figure 2). We then decided to determine in which part
of the cell cycle JLK1486 might exert its cytostatic effects in glioma
cells. The IC50 growth-inhibitory concentration for JLK1486 was
∼80 nM in Hs683, ∼290 nM in T98G, and ∼180 nM in U373
glioma cell lines (Figure 1B). We used the same concentration (i.e.,
100 nM) to analyze the cytostatic effects of JLK1486 in the three
glioma cell lines under study. We first investigated whether 100 nM
JLK1486 induced proapoptotic, thus cytotoxic, effects in Hs683,
T98G, and U373 glioma cells. Figure 3A shows that JLK1486 did
not induce such proapoptotic effects, whereas narciclasine, the positive
control in PC3 prostate cancer cells, did it. Thus, flow cytometry–
(Figure 3A) and quantitative videomicroscopy– (Figure 2) related data
perfectly fit together with respect to the fact that JLK1486 exerts its
in vitro growth-inhibitory activity through cytostatic, not cytotoxic, ef-
fects. Flow cytometry analyses failed in revealing JLK1486-induced
modifications at 100 nM in Hs683, T98G, and U373 cell cycle ki-
netics (Figure 3B). However, compound-induced effects on mitosis are
rather difficult to detect by means of flow cytometry. We thus used
quantitative videomicroscopy to analyze JLK1486-induced effects on
the percentages of glioma cells in the mitotic phase. Figure 3C illus-
trates the morphology of mitoses whose percentages have been quan-
tified (see Materials and Methods) in control and JLK1486-treated
conditions. Figure 3D clearly indicates that 100 nM JLK1486 de-
creased mitotic rates in the three glioma cell lines under study. Al-
together, data in Figures 2 and 3 point to mitosis as an important
target of JLK1486-induced cytostatic effects in glioma cells.
JLK1486-Induced Cytostatic Activity in Glioma Cells Does
Not Seem to Relate to Kinase Activity Inhibition
The fact that JLK1486 markedly impairs glioma cell proliferation
(Figures 2 and 3, A and B) without apparent cytotoxic effects (Fig-
ures 2 and 3, C and D) prompted us to investigate whether JLK1486
might impair the activity of kinases involved either in cell cycle con-
trol or, more precisely, in mitosis control. Data from the present
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study revealed that 100 nM JLK1486 did not decrease by 50% the
activity of any kinase of a panel of 256 kinases that were assayed
(Table W2). Whereas the human kinome includes roughly double
the number of kinases as the array assayed here, the current data
suggest that it is unlikely that JLK1486 impairs glioma cell prolifer-
ation through the targeting of kinases implicated in cell cycle and/or
mitosis control.
JLK1486 Transiently Activates PPARγ
We made use of a Transcription Factor Array to investigate whether
JLK1486 could target certain transcription factors implicated in cell
proliferation (Table 1). Indeed, data in Table 1 show that 100 nM
JLK1486 increased the activity of a dozen transcription factors whose
activity directly regulate cell proliferation by two- to fivefold, with
most of them targeting mitosis. We made use of biochemical analyses
to validate, at least partly, the data provided in Table 1. Data in Figure 4
show that 100 nM JLK1486 transiently activated PPARγ while hav-
ing weak or no effects on PPARα and PPARβ/δ.
Docking experiments confirmed that JLK1486 possesses a theo-
retical binding affinity for PPARs, including PPARγ, similar to that
displayed by two PPARγ agonists, namely, troglitazone and rosiglita-
zone (Table W3). However, the fact that i) JLK1486 displays higher
in vitro growth inhibitory activity than troglitazone and rosiglitazone
(Figure 1B) and ii) JLK1486-induced effects on PPARγ activation
are ranked seventh only among the 11 transcription factors whose
activity is modified by JLK1486 (Table 1) strongly suggests that
PPAR modulation is not the main mechanism by which JLK1486
exerts its cytostatic effects in glioma cells. In addition, the transient
JLK1486-induced activation of PPARγ (Figure 4C ) was not strong
enough to decrease any cell cycle–related kinase activity, including
CDK1, CDK2, and CDK4 (Table W2), whose activities are usually
decreased on full PPARγ activation [35].
JLK1486 Activates Myt1 and STAT1
Data in Table 1 indicate that Myt1 and STAT1 may be important
targets of JLK1486 in glioma cells in its cytostatic effects. We did not
find three-dimensional structures of Myt1 in any databases, and we
therefore focused our attention on STAT1, which was ranked second
among 11 transcription factors targeted by JLK1486 (Table 1).
Molecular docking experiments revealed that both JLK1486 and
Cpd30-12 (see Figure 1A), a selective ligand for STAT1 [34], displayed
higher binding energy for STAT1 ( JLK1486 = −11.4 kcal/mol;
Cpd30-12 = −11.9 kcal/mol) than for STAT3 ( JLK1486 = −9.6 kcal/
mol; Cpd30-12 = −10.5 kcal/mol). On the basis of these data, it seems
that JLK1486 displays a higher selectivity for STAT1 than Cpd30-12.
We first examined the best poses of Cpd30-12 docked in STAT1
(Figure 5B). The best solutions found are convergent if one considers
the benzoic acid group of the ligand, whereas the heterocyclic ring
has several possible poses. An H-bond appears between the ligand car-
boxylate and R602, whereas electrostatic interactions between E605,
S606, A630, and E632 further stabilize the benzoic and the furyl
rings (Figure 5B). One of the oxygens of the heterocycle presents an
H-bond toward S606, whereas the receptor surface adapted its shape to
fit the different poses with S604 and S606 side chain flexibility
(Figure 5B). We then examined the best poses of JLK1486 docked
in STAT1. The ligand lies in a groove, with the trifluoromethylbenzene
Figure 2. Morphologic illustrations of JLK1486-induced effects in human HS683 glioblastoma cells. Computer-assisted phase-contrast
microscopy (quantitative videomicroscopy) was used to characterize the growth-inhibitory effects of JLK1486 in Hs683 glioblastoma cell
populations. The top panel represents illustrations of Hs683 glioblastoma cells that were left untreated (control), whereas the bottom
panel represents illustrations of Hs683 glioblastoma cells treated with 100 nM JLK1486.
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Figure 3. Analyses of JLK1486-induced effects in Hs683, U373, and T98G glioma cell proliferation versus apoptosis. (A) Flow cytometry
analyses of apoptotic rates in glioma cells left untreated (control) or treated for 72 hours with 100 nM JLK1486; 1 μM narciclasine was
used as a positive control (72 hours of treatment) in human PC3 prostate cancer cells. (B) Flow cytometry analyses of cell cycle kinetics
(the percentages of cells in the G1, S, and G2 phases) in glioma cells left untreated (control) or treated for 72 hours with 100 nM JLK1486.
(C) Illustrations of the morphological appearance of mitoses (M) in a U373 glioma cell population. (D) Quantitative videomicroscopy
analyses of 100 nM JLK1486-induced effects on mitosis rates of glioma cells. Data are presented as mean ± SEM. Values were cal-
culated in triplicate.
Table 1. JLK1486-Induced Effects at 100 nM for 24 Hours on the Activity of Various Transcription Factors.
Factor Name Description Function T/CT
MyT1 Myelin transcription factor 1 Phosphorylates Cdc2 4.8
STAT1 p84/p91 Signal transducer and activator of transcription 1, 84 kDa (β)/91 kDa (α) Antiproliferative/proapoptotic isoform STAT1α and proliferative isoform
STAT1β play a crucial role in the regulation of cell cycle
4.1
ICSBP Interferon consensus sequence binding protein (IRF-8) Stable transfection with ICSBP inhibits lens carcinoma cell growth by
upregulating caspase-1, p21waf/cip1, and p27Kip1 expression
3.5
v-Maf v-maf musculoaponeurotic fibrosarcoma oncogene homolog (avian) Overexpression of v-Maf activates p53 expression, which can lead to cell
cycle arrest
3.1
C/EBP a/g CCAAT/enhancer binding protein α, γ Inhibits cell proliferation through p21waf/cip1 2.8
WT1 Wilms tumor 1 Upregulates p21waf/cip1 (inhibitor of G1/S progression) and downregulates
cyclin E (promoter of cell cycle progression)
2.8
PPAR Peroxisome proliferative–activated receptor Inhibits proliferation through cyclin D1; cyclin-dependent kinases 1, 2, and 4,
Ki-67, and proliferating cell nuclear antigen
2.8
IRF-1 Interferon regulatory factor 1 Expression of IRF-1 in different mammalian cell lines leads to down-regulation
or stop of proliferation
2.3
NPAS2 Neuronal PAS domain protein 2 Knockdown of NPAS2 in cancer cells represses the expression of FANCG
(cell cycle checkpoint control) and MAPK2 (cell cycle arrest)
2.2
AP-2 Activating enhancer binding protein 2 Inhibits cancer cell growth and activates p21waf/cip1 expression 2.1
HEN1 NHLH1 (nescient helix loop helix 1) Prevents some postmitotic cells from reentering the cell cycle (neurogenesis) 2.0
T/CT indicates “treated/control.”
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pointing toward a polar pocket composed of K584, E587, R588,
T615, and F628, forbidding further interaction with the pY binding
site (Figure 5C ). One of the quinoline rings is also directed toward
K584 and makes an H-bond with S604 and T613 (Figure 5C ). The
other quinoline rings interact with D627, F628, and H629 as poten-
tials hydrogen bonding residues, whereas the methyl side chain of
A630 has an electrostatic effect with the aromatic ring (Figure 5C ).
Altogether, these data show that interactions of STAT1 with JLK1486
and Cpd30-12 are slightly different, but both ligands secure the pY
binding site, whereas the hydrophobic pocket adapts its shape to the
different molecules. We next performed the same analyses for STAT3;
the data revealed that the ligand binding modes are quite different, sug-
gesting that JLK1486 can probably inhibit any interaction with the pY
binding site, whereas Cpd30-12 may not (data not shown).
Data presented in Figure 6 represent biochemical validations of the
data presented in Table 1 and Figure 5. These data show that 100 nM
JLK1486 markedly activated phospho-STAT1 in human U373 GBM
cells after 24 hours of treatment and even slightly increased STAT1
protein expression (Figure 6A). We failed to demonstrate JLK1486-
mediated activation of p21 because p21 is not expressed in human
Figure 4. Characterization of the potential effects of JLK1486 on PPARα, β/δ, and γ activation. Whether JLK1486 (100 nM) is able to
activate PPARs was investigated after 4 and 24 hours of treatment in U373 glioblastoma cells (Ab; Bb; Cb). The left panel represents the
controls used to validate the assay (Aa; Ba; Ca). CTNEG and CTPOS represent the negative and the positive controls, respectively, provided
by the manufacturer. CTPOS + COMP represents an experimental condition in which a competitor (COMP) provided by the manufacturer
was added in the same time than the CTPOS. CT 4h and CT 24h represent the control values in U373 glioma cells left untreated. There are
these control values that have been arbitrarily normalized at 100% in the right panel. Data are presented as mean ± SEM. Values were
calculated in triplicate.
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U373 and T98G GBM cell lines, whereas it is already expressed at
very high levels in Hs683 GBM cells (Figure 6B).
JLK1486-Induced Antitumor Effects In Vivo
Figure 7 shows that long-term i.v. administration of 10 mg/kg
JLK1486 contributed similar therapeutic benefits when compared
with long-term i.v. administration of TMZ in a human Hs683 glioma
model in which glioma cells are orthotopically xenografted into the
brains of immunocompromised mice. The same features were ob-
served when comparing chronic per os administrations of 20 mg/kg
JLK1486 to 80 mg/kg TMZ (Figure 7).
Discussion
Despite a large number of new and sometimes very innovative ap-
proaches [20], treatment options for malignant gliomas, including
glioblastomas, are still very limited [3,9], calling for further develop-
ment of therapeutic strategies.
The current study relies on two previous studies from our group
aimed at the development of novel hydroxyquinoline compounds as
anticancer agents [21,36]. Hydroxyquinoline is a privileged struc-
tural moiety observed in many biologically active natural products,
and it is used as a source for many drugs targeting a wide range of
pathologies, including neurodegenerative, parasitic amoebic dysen-
tery, and herpesvirus diseases [21]. We thus first reported preliminary
Figure 5. Docking of JLK1486 and Cpd30-12 in STAT1. (A) Sequence alignment of STAT1 and STAT3 (flexible residues are highlighted in
red). (B) Consensus pose for Cpd30-12 is shown; electrostatic interactions with the receptor stabilize the benzoic ring and the hetero-
cycle. The latter is able to adopt different orientations, whereas the aromatic ring is always in the same place (C). Consensus poses for
JLK1486 stabilized by several H-bond and hydrophobic interactions. Illustrations were prepared with Pymol Molecular Graphics System
(Version 1.2rl; Schrödinger, LLC).
Figure 6. Characterization of the effects of JLK1486 on STAT1 and
p21 activation. Western blot analyses of 100 nM JLK1486-mediated
effects on levels of STAT1 expression and activation in human U373
GBM cells (A) and on levels of p21 expression in human U373,
T98G, and Hs683 GBM cells (B). Tubulin was used as an inter-
nal control of protein quality. STAT1 exists in two forms: STAT1α
(91 kDa) and STAT1β (84 kDa).
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data on the anticancer activity of a family of bis 8-hydroxyquinoline–
substituted benzylamines [36]. We then enlarged the initial panel of
these bis 8-hydroxyquinoline benzylamine analogs to proceed with
SAR analyses for in vitro anticancer activity; JLK1486 seemed as a
potential hit in anticancer activity, at least in vitro [21]. Our previous
study also pointed to the fact that JLK1486-induced anticancer ac-
tivity occurred through cytotoxic effects in carcinoma cells, whereas
this anticancer activity of JLK1486 turned out to be cytostatic in
U87 glioma cells in vitro [21]. The present study confirms the cyto-
static effects of JLK1486 in Hs683, T98G, and U373 glioma cells.
The present study further reveals that these JLK1486-mediated cyto-
static effects seem to occur, at least partly, through the activation of
various transcription factors that in turn activate antiproliferative
genes (Table 1). In contrast, JLK1486 does not seem to directly tar-
get kinases (Table W2).
PPARγ could be one of the transcription factors activated by
JLK1486. Molecular docking experiments revealed similar potential
affinity for PPARγ when compared with two thiazolidinediones
(TDZs), namely, troglitazone and rosiglitazone (Table W3). As em-
phasized by Seufert et al. [37], there is increasing evidence that PPARγ
agonists, including TDZs and non-TDZs, block the motility and in-
vasiveness of glioma cells. GW7845, an investigational non-TDZ
PPARγ ligand, binds and activates human PPARγ at nanomolar con-
centrations and thus possesses a higher potency than TDZs, such as
pioglitazone, troglitazone, rosiglitazone, and the experimental PPARγ
agonist ciglitazone, which require submicromolar doses [37]. Grommes
et al. [38] demonstrated that 30 μM GW7845 reduced the viability of
rat C6 and human U87 and A172 glioma cells through cell cycle arrest
and increased cell death. The data presented here show that these ef-
fects are achieved with 0.1 μM JLK1486 [38]. Grommes et al. [38]
also demonstrated for the first time that the activation of PPARγ by
GW845 leads to inhibition of the migration and invasion abilities of
C6 rat glioma cells in vitro. A subsequent study revealed that the FDA-
approved TDZ pioglitazone exhibits antiglioma properties similar to
GW7845 [37]. Ciglitazone also induces apoptosis in glioma cells [39].
Apart from the cytostatic effects we report here for JLK1486, we also
observed that this compound markedly impaired Hs683, T98G, and
U373 glioma cell migration at concentrations below 0.1 μM in vitro
(data not shown), as revealed by quantitative videomicroscopy-related
wound healing assays [29]. However, if PPARγ could be one of the
antiproliferative transcription factors activated by JLK1486, it seems
obvious that PPARγ is not the sole target of JLK1486 (Table 1).
The major antiproliferative transcription factor targeted by JLK1486
seems to be Myt1 (Table 1), which controls the progress of cells into
and out of mitosis [40]. Myt1 also helps cancer cells to react against the
adverse effects of chemotherapeutic agents through G2 arrest [41]. We
did not investigate Myt1 in the present study because we were unable
to visualize Myt1-JLK1486 interactions because of a lack of available
three-dimensional Myt1 structures in protein databases. We are cur-
rently developing an original pharmacological approach aimed at char-
acterizing how JLK1486 modulates Myt1 activity in glioma cells.
Another major candidate for JLK1486’s cytostatic effects is STAT1
(Table 1 and Figure 6A). Signal transducers and activators of tran-
scription (STATs) are latent cytoplasmic transcription factors that
mediate various biologic responses, such as cell proliferation, survival,
apoptosis, and differentiation [42]. Seven STATs are known in mam-
mals, that is, STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B,
and STAT6 [43].
STAT1 is usually considered to be a tumor suppressor, whereas
STAT3 is considered an oncogene, and its constitutive inactivation is
reported in nearly 70% of solid and hematological tumors [44]. Indeed,
dysregulation of STAT1 signaling seems to be associated with the de-
velopment of cancer [42]. However, if it is true that STAT1-deficient
mice spontaneously develop tumors, the fact also remains that consti-
tutively activated STAT1 signaling is present in a number of human
cancers [45]. In contrast to STAT1, inhibition of persistent STAT3 ac-
tivation by blocking tyrosine kinase activity has been repeatedly asso-
ciated with selective tumor growth suppression and cell death [45].
On cytokine and growth factor stimulation, cytoplasmic STAT
molecules become activated through tyrosine phosphorylation, dimer-
ize through reciprocal phosphotyrosine (pTyr)–SH2 interactions, accu-
mulate in the nucleus, bind to DNA, and activate gene transcription
[43]. Subsequent inactivation involves phospho-STATs dissociating
from DNA, becoming dephosphorylated, and exported to the cyto-
plasm [43]. STAT1 and STAT3 activation is reciprocally regulated,
and perturbation of their expression or phosphorylation levels may re-
direct cytokine/growth factor signals from proproliferative to proapop-
totic [44]. In fact, both STAT1 and STAT3 can exert their opposing
effects on tumorigenesis either directly, through transcriptional regula-
tion of target genes in the cancer cells, or indirectly, by modulating
tumor angiogenesis or the antitumor immune response [44].
Accumulating evidence now supports an important role for STAT1
in various forms of cell death, encompassing both apoptotic and
nonapoptotic pathways [42]. STAT1-dependent apoptosis is mediated
by the induction of the interferon regulatory factor 1 (IRF-1) and in-
volves regulation of the expression of members of the cell surface death
receptor family and their ligands, namely, Fas, FasL, TNF-related
apoptosis–inducing ligand and its receptor KILLER/DR5, caspases, both
at the basal level and on stimulation by cytokines and iNOS [44]. STAT1
also negatively regulates the cell cycle by inducing the CDK inhibitors
p21waf/cip1 and p27Kip-1 and by downregulating the expression of
c-myc and several cyclins [44]. Data in Figure 6A confirm these data
by illustrating the fact that JLK1486 actually activates STAT1.
Figure 7. Characterization of the in vivo anticancer activity of
JLK1486 versus TMZ (reference compound) in Hs683 xenografts.
Human Hs683 glioblastoma cells were orthotopically grafted into
the brains of immunocompromised mice (11 mice per experimen-
tal group). The mice in the control group were left untreated,
whereas the mice of the four remaining groups were treated either
orally (p.o.) or intravenously (i.v.) with JLK1486 and TMZ three
times a week (Monday, Wednesday, Friday) for three consecutive
weeks, with treatment starting on the fifth day after graft.
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Data in Table 1 show that, apart from activating STAT1, JLK1486
also activated four other growth factors that directly or indirectly ac-
tivate p21waf/cip1, namely, AP-2, WT1, C/EBPa/g, and ICSBP. Thus,
data presented here show that JLK1486 activates STAT1 (Table 1 and
Figure 6A) and molecular docking experiments strongly suggest a
higher selectivity of JLK1486 for STAT1 than for STAT3 (Figure 5).
Moreover, the data argue in favor of the fact that JLK1486-induced
activation of STAT1 leads to negative regulation of the cell cycle
(and thus to cytostatic effects) rather than to the activation of apopto-
sis (and thus to cytotoxic effects). Indeed, JLK1486 impairs glioma
cell proliferation, whereas not resulting in cell death, during a frame
of 3 days of observation (Figures 2 and 3). Glioma cell death occurs
7 days after JLK1486 treatment at its IC50 growth-inhibitory concen-
tration (data not shown), a feature that is likely a consequence of pro-
longed cell growth arrest rather than direct cell killing.
So far, drugs that activate STAT1 rather than inhibit STAT1 sig-
naling have not been characterized. Finding such drugs would be
very interesting and JLK1486 could be such a candidate. However,
it is difficult to mechanistically understand how a drug binding to the
SH-2 domain of STAT1 could activate STAT1 rather than act as an
inhibitor. In fact, the drug Cpd30-12, which, by modeling, was
linked to similar docking site as JLK1486, is a described inhibitor
of STAT1 rather than an activator [34]. It must be emphasized that
in our hand, Cpd30-12 binding pose differed slightly from the one
already reported [34]: the benzoic acid group points toward R602
with our model, a feature that can be accounted to the allowed flex-
ibility of the receptor in our study, leading to different poses.
We will pay a particular attention to STAT1 in the next experiments
we will perform with JLK1486 to further decipher its mechanisms of
anticancer action. In the same manner, we did not yet experimentally
explore the effect of JLK1486 to the related STAT3, which might be
also a potential relevant target, and these experiments will also be
conducted in the next steps because the role of STAT3 in gliomas is
already well documented [46].
In conclusion, whether the observed activation of various tran-
scription factors (Myt1, STAT1, and PPARγ) by JLK1486 is due to
a general up-regulation of stress pathways in the glioma cells after drug
treatment or directly linked to the cytostatic action of the drug remains
an open question. However, the data of the current study clearly point
to the fact that JLK1486 exerts cytostatic, not cytotoxic, effects in gli-
oma cells. JLK1486 mediated anticancer activity in vivo (through i.v.
as well as oral routes of administrations) in an orthotopic human gli-
oma xenograft model with efficiency similar to that of TMZ, the cri-
terion standard in glioma treatment. Whether such compounds could
provide additive versus synergistic effects in combination with TMZ
remains to be determined.
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Table W1. List of Kinase and Substrates and Experimental Protocol and References.
No. Kinase Lot Conc. (ng/50 μl) Substrate Lot Conc. (μg/50 μl)
1 ABL1 T315I 2 50 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.25
2 ABL1 wt 3 25 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
3 ABL2 1 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.25
4 ACK1 3 50 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
5 ACV-R1 1 20 GSK3(14-27) 8 2
6 ACV-R1B 2 5 RBER-CHKtide 24 4
7 ACV-RL1 1 20 Casein SIG_83K7430 1
8 AKT1 7 25 GSK3(14-27) 8 2
9 AKT2 3 200 GSK3(14-27) 6 1
10 ALK 2 25 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
11 AMPK-alpha1 fl 1 200 RBER-CHKtide 23 2
12 Aurora-A 4 50 tetra(LRRWSLG) 5 0.5
13 Aurora-B 7 100 tetra(LRRWSLG) 5 0.25
14 Aurora-C 8 200 tetra(LRRWSLG) 4 0.25
15 AXL 3 50 Poly(Glu,Tyr)4:1 SIG_20K5903 0.25
16 BLK 1 100 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
17 BMX 3 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.25
18 B-RAF V600E 1 25 MEK1-KM (kinase-dead) 21 0.5
19 B-RAF wt 1 20 MEK1-KM (kinase-dead) 22 0.5
20 BRK 4 25 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
21 BRSK1 1 3 RBER-CHKtide 24 2
22 BTK 2 25 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
23 CAMK1D 1 100 RBER-CHKtide 24 1
24 CAMK2A 1 2 RBER-CHKtide 23 2
25 CAMK2B 1 100 RBER-CHKtide 022.1 2
26 CAMK2D 1 2 RBER-CHKtide 022.1 2
27 CAMK4 1 150 JUN 3 0.5
28 CAMKK2 1 10 GSK3(14-27) 6 2
29 CDC42BPA 1 10 S6-peptide 4 1
30 CDC42BPB 1 25 S6-peptide 4 1
31 CDK1/CycA 5 10 RBER-CHKtide 22 2
32 CDK1/CycB1 25 25 RBER-CHKtide 24 2
33 CDK1/CycE 1 50 RBER-CHKtide 22 2
34 CDK2/CycA 5 25 RBER-CHKtide 24 1
35 CDK2/CycE 9 10 RBER-CHKtide 9 1
36 CDK3/CycE 1 10 RBER-CHKtide 23 1
37 CDK4/CycD1 7 20 RBER-CHKtide 24 2
38 CDK4/CycD3 1 10 RBER-CHKtide 24 1
39 CDK5/p25NCK 1 15 RBER-CHKtide 24 1
40 CDK5/p35NCK 1 15 RBER-CHKtide 24 1
41 CDK6/CycD1 4 200 RBER-CHKtide 24 2
42 CDK7/CycH/MAT1 2 25 RBER-CHKtide 24 2
43 CDK8/CycC 2 50 RBER-CHKtide 1 1
44 CDK9/CycT 4 15 RBER-CHKtide 22 1
45 CHK1 2 50 RBER-CHKtide 17 2
46 CHK2 2 10 tetra(LRRWSLG) 4 0.5
47 CK1-alpha1 1 100 Casein SIG_65K7410 1
48 CK1-delta 1 5 Casein SIG_65K7410 1
49 CK1-epsilon 1 2,5 Casein SIG_83K7430 0.5
50 CK1-gamma1 1 5 Casein SIG_65K7410 1
51 CK1-gamma2 1 5 Casein SIG_83K7430 1
52 CK1-gamma3 1 5 Casein SIG_83K7430 1
53 CK2-alpha1 3 20 Casein SIG_83K7430 1
54 CK2-alpha2 1 50 Casein SIG_65K7410 1
55 CLK1 1 400 H2O (Autophos.) 0 0
56 COT 18 300 RBER-CHKtide 24 3
57 CSF1-R 4 25 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
58 CSK 1 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
59 DAPK1 2 40 GSK3(14-27) 8 2
60 DAPK2 1 10 S6-peptide 4 2
61 DAPK3 1 5 GSK3(14-27) 6 2
62 DCAMKL2 1 10 RBER-CHKtide 24 1
63 DDR2 2 50 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.25
64 DMPK 1 200 tetra(LRRWSLG) 5 2
65 DYRK1A 2 5 RBER-CHKtide 24 2
66 DYRK1B 1 2 RBER-CHKtide 23 2
67 EEF2K 1 1 GSK3(14-27) 6 4
68 EGF-R L858R 1 5 Poly(Glu,Tyr)4:1 SIG_20K5903 0.25
69 EGF-R T790M 1 10 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
70 EGF-R T790M/L858R 1 10 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
71 EGF-R wt 15 10 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
72 EIF2AK2 2 10 Rb-CTF 13 1
73 EIF2AK3 1 10 MEK1-KM (kinase-dead) SIG_83K7430 2
Table W1. (continued )
No. Kinase Lot Conc. (ng/50 μl) Substrate Lot Conc. (μg/50 μl)
74 EPHA1 1 50 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
75 EPHA2 1 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
76 EPHA3 1 150 Poly(Glu,Tyr)4:1 SIG_20K5903 0.25
77 EPHA4 1 150 Poly(Glu,Tyr)4:1 SIG_20K5903 0.25
78 EPHA5 1 5 Poly(Glu,Tyr)4:1 SIG_20K5903 0.5
79 EPHA7 1 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
80 EPHA8 1 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
81 EPHB1 1 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
82 EPHB2 6 100 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
83 EPHB3 1 25 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
84 EPHB4 7 10 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
85 ERBB2 12 100 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
86 ERBB4 7 40 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
87 ERK1 2 5 RBER-CHKtide 24 2
88 ERK2 4 10 RBER-CHKtide 24 2
89 FAK 15 40 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
90 FER 2 10 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
91 FES 2 5 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
92 FGF-R1 V561M 2 10 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.25
93 FGF-R1 wt 11 40 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
94 FGF-R2 1 5 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
95 FGF-R3 4 100 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
96 FGF-R4 6 50 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
97 FGR 1 50 Poly(Glu,Tyr)4:1 SIG_20K5903 50
98 FLT3 D835Y 3 10 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.5
99 FLT3 ITD 1 100 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
100 FLT3 wt 11 50 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
101 FRK 1 25 Poly(Glu,Tyr)4:1 SIG_20K5903 0.5
102 FYN 2 10 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
103 GRK2 1 50 Casein SIG_65K7410 0.5
104 GRK3 1 10 Casein SIG_65K7410 2
105 GRK4 1 5 Casein SIG_65K7410 0.5
106 GRK5 1 5 Casein SIG_83K7430 1
107 GRK6 2 10 Casein SIG_65K7410 1
108 GSK3-alpha 1 50 RBER-CHKtide 24 4
109 GSK3-beta 3 50 RBER-CHKtide 24 1
110 HCK 1 25 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
111 HIPK1 1 20 RBER-CHKtide 24 2
112 HIPK3 1 20 RBER-CHKtide 24 2
113 HRI 1 100 Casein SIG_83K7430 0.5
114 IGF1-R 12 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
115 IKK-alpha 3 50 RBER-CHKtide 23 2
116 IKK-beta 5 100 RBER-CHKtide 24 1
117 IKK-epsilon 6 20 GSK3(14-27) 8 1
118 INS-R 6 10 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
119 INSRR 1 150 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.25
120 IRAK1 2 10 RB-CTF 13 2
121 IRAK4 6 20 Histone H2B SIG_87H7445 0.25
122 ITK 1 100 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
123 JAK2 7 100 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
124 JAK3 2 200 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
125 JNK1 5 5 ATF2 6 0.25
126 JNK2 3 5 ATF2 6 0.25
127 JNK3 4 5 ATF2 6 0.25
128 KIT T670I 2 100 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
129 KIT wt 8 50 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
130 LCK 3 50 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
131 LIMK1 1 50 RBER-CHKtide 23 2
132 LTK 1 50 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
133 LYN 1 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
134 MAP4K4 1 5 Casein SIG_83K7430 0.5
135 MAPKAPK3 1 20 tetra(LRRWSLG) 4 0.25
136 MAPKAPK5 5 10 RBER-CHKtide 23 4
137 MARK1 1 100 RBER-CHKtide 23 1
138 MARK2 2 4,5 RBER-CHKtide 23 2
139 MARK3 1 100 RBER-CHKtide 17 1
140 MATK 1 5 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
141 MEK1 wt 2 50 ERK2-KR (kinase-dead) 6 2
142 MELK 1 100 RBER-CHKtide 23 2
143 MERTK 1 50 Poly(Glu,Tyr)4:1 SIG_20K5903 0.5
144 MET 12 25 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
145 MET T1250M 1 20 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
146 MINK1 2 10 RBER-CHKtide 24 1
Table W1. (continued )
No. Kinase Lot Conc. (ng/50 μl) Substrate Lot Conc. (μg/50 μl)
147 MKK6 S207D/T211D 1 50 p38-alpha-KA (kinase-dead) 1 1
148 MST1 2 5 RB-CTF 13 2
149 MST2 3 10 RB-CTF 13 2
150 MST3 1 20 Casein SIG_65K7410 1
151 MST4 1 100 RB-CTF 13 1
152 mTOR 1 20 Casein SIG_65K7410 1
153 MUSK 3 150 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
154 MYLK2 1 10 S6-peptide 4 1
155 NEK1 1 3 RBER-CHKtide 24 4
156 NEK11 1 25 Myelin Basic Protein MIL_28053 2
157 NEK2 2 100 RB-CTF 13 1
158 NEK3 1 5 S6-peptide 4 2
159 NEK6 1 20 GSK3(14-27) 7 2
160 NEK7 2 15 Casein SIG_83K7430 1
161 NIK 3 200 RBER-CHKtide 24 2
162 NLK 2 15 GSK3(14-27) 9 2
163 p38-alpha 5 10 ATF2 6 0.5
164 p38-beta 4 3 ATF2 10 1
165 p38-delta 1 2 RBER-CHKtide 24 2
166 P38-gamma 1 2,5 RB-CTF 13 1
167 PAK1 2 15 tetra(LRRWSLG) 6 1
168 PAK2 1 50 tetra(LRRWSLG) 5 0.25
169 PAK3 1 20 tetra(LRRWSLG) 5 0.5
170 PAK4 3 50 tetra(LRRWSLG) 6 0.5
171 PAK6 1 50 tetra(LRRWSLG) 4 0.125
172 PAK7 1 50 tetra(LRRWSLG) 4 0.25
173 PASK 1 50 RBER-CHKtide 17 2
174 PBK 3 200 Histone H1 SIG_94H8010 0.5
175 PCTAIRE1 4 400 RBER-CHKtide 23 2
176 PDGFR-alpha 9 50 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
177 PDGFR-beta 13 50 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
178 PDK1 2 20 tetra(LRRWSLG) 5 0.25
179 PHKG2 1 10 RBER-CHKtide 24 4
180 PIM1 3 10 GSK3(14-27) 8 1
181 PIM2 2 50 GSK3(14-27) 7 2
182 PKA 2 5 tetra(LRRWSLG) 5 0.5
183 PKC-alpha 5 2,5 PKC(19-31) 2 0.25
184 PKC-beta1 4 2,5 PKC(19-31) 2 0.25
185 PKC-beta2 3 5 PKC(19-31) 2 0.25
186 PKC-delta 4 50 PKC(19-31) 2 0.5
187 PKC-epsilon 6 10 PKC(19-31) 2 0.5
188 PKC-eta 5 20 Histone H2B SIG_87H7445 0.25
189 PKC-gamma 7 10 MEK1-KM (kinase-dead) 2 0.25
190 PKC-iota 6 100 PKC(19-31) 2 0.5
191 PKC-mu 4 12,5 RBER-CHKtide 23 2
192 PKC-nu 2 50 tetra(LRRWSLG) 6 0.125
193 PKC-theta 8 2,5 PKC(19-31) 2 0.25
194 PKC-zeta 5 50 PKC(19-31) 2 0.5
195 PLK1 13 50 RBER-CHKtide 17 2
196 PLK3 1 30 Casein SIG_65K7410 0.5
197 PRK1 4 25 RBER-CHKtide 23 2
198 PRK2 1 10 RBER-CHKtide 24 4
199 PRKD2 1 3 RBER-CHKtide 24 4
200 PRKG1 1 5 PKC(19-31) 2 1
201 PRKG2 1 1 GSK3(14-27) 6 4
202 PRKX 1 10 GSK3(14-27) 6 4
203 PYK2 1 75 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
204 RAF1 Y340D/Y341D 1 10 MEK1-KM (kinase-dead) 21 0.5
205 RET 1 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
206 RIPK2 3 50 RBER-CHKtide 24 2
207 ROCK1 2 4 PKC(19-31) 2 1
208 ROCK2 2 2,5 S6-peptide 4 2
209 RON 2 2,5 p38-alpha-KA (kinase-dead) 3 1
210 ROS 1 15 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
211 RPS6KA1 2 10 RBER-CHKtide 23 2
212 RPS6KA2 1 5 tetra(LRRWSLG) 5 0.5
213 RPS6KA3 2 5 MEK1-KM (kinase-dead) 4 0.25
214 RPS6KA4 1 50 RBER-CHKtide 17 2
215 RPS6KA5 1 25 RBER-CHKtide 17 2
216 RPS6KA6 1 2 GSK3(14-27) 8 2
217 S6K 6 50 GSK3(14-27) 6 4
218 S6K-beta 1 100 RBER-CHKtide 24 4
219 SAK 3 100 p38-alpha-KA (kinase-dead) 4 4
Table W1. (continued )
No. Kinase Lot Conc. (ng/50 μl) Substrate Lot Conc. (μg/50 μl)
220 SGK1 4 200 GSK3(14-27) 7 1
221 SGK2 1 20 GSK3(14-27) 6 1
222 SGK3 4 50 GSK3(14-27) 9 1
223 SNARK 1 100 Histone H2B SIG_87H7445 0.5
224 SNF1LK2 1 2,5 RBER-CHKtide 24 2
225 SNK 5 50 GSK3(14-27) 7 2
226 SRC 4 10 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
227 SRPK1 1 200 MEK1-KM (kinase-dead) UPS_DAM1475041 1
228 SRPK2 1 200 Myelin Basic Protein UPS_DAM1475041 1
229 STK17A 1 25 RB-CTF 13 4
230 STK23 2 25 RBER-CHKtide 24 4
231 STK33 1 50 RBER-CHKtide 24 2
232 SYK 3 100 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
233 TAOK2 2 10 Casein SIG_83K7430 1
234 TAOK3 5 50 PKC(19-31) 2 0.5
235 TBK1 2 5 Casein SIG_65K7410 1
236 TEC 1 200 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
237 TGFB-R1 3 10 GSK3(14-27) 8 1
238 TIE2 7 10 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
239 TRK-A 1 50 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
240 TRK-B 4 10 Poly(Glu,Tyr)4:1 SIG_20K5903 0.25
241 TRK-C 5 10 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
242 TSF1 2 25 Casein SIG_65K7410 1
243 TSK2 2 25 RBER-CHKtide 21 2
244 TSSK1 1 3 RBERvCHKtide 24 2
245 TTK 3 100 RBER-CHKtide 23 1
246 TYK2 1 80 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
247 TYRO3 1 25 Poly(Glu,Tyr)4:1 SIG_20K5903 0.5
248 VEGF-R1 9 50 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
249 VEGF-R2 15 25 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
250 VEGF-R3 12 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
251 VRK1 1 50 RBER-CHKtide 21 2
252 WEE1 5 200 Poly(Ala,Glu,Lys,Tyr)6:2:5:1 SIG_53H5516 0.125
253 WNK2 1 30 RBER-CHKtide 24 2
254 WNK3 1 10 S6-peptide 4 2
255 YES 1 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
256 ZAP70 1 20 Poly(Glu,Tyr)4:1 SIG_20K5903 0.125
Table W2. Kinase Residual Activity after Treatment with 100 nM JLK1486.
ABL1 T315I 98
ABL1 wt 92
ABL2 95
ACK1 104
ACV-R1 98
ACV-R1B 97
ACV-RL1 110
AKT1 103
AKT2 107
AKT3 109
ALK 113
AMPK-α1 f l 103
ARK5 99
Aurora-A 96
Aurora-B 102
Aurora-C 106
AXL 104
BLK 96
BMX 98
B-RAF V600E 102
B-RAF wt 90
BRK 106
BRSK1 114
BTK 120
CAMK1D 121
CAMK2A 83
CAMK2B 78
CAMK2D 95
CAMK4 103
CAMKK2 119
CDC42BPA 102
CDC42BPB 95
CDK1/CycA 96
CDK1/CycB1 121
CDK1/CycE 102
CDK2/CycA 92
CDK2/CycE 91
CDK3/CycE 96
CDK4/CycD1 93
CDK4/CycD3 105
CDK5/p25NCK 99
CDK5/p35NCK 90
CDK6/CycD1 88
CDK7/CycH/MAT1 45
CDK8/CycC 69
CDK9/CycT 98
CHK1 110
CHK2 76
CK1-α1 67
CK1-δ 100
CK1-ɛ 109
CK1-γ1 96
CK1-γ2 105
CK1-γ3 106
CK2-α1 105
CK2-α2 94
CLK1 90
COT 88
CSF1-R 95
CSK 112
DAPK1 177
DAPK2 83
DAPK3 75
DCAMKL2 70
DDR2 76
DMPK 88
DYRK1A 98
EEF2K 106
EGF-R L858R 99
EGF-R T790M 112
EGF-R T790M/L858R 104
EGF-R wt 115
EIF2AK2 99
EIF2AK3 99
EPHA1 108
Table W2. (continued )
EPHA2 107
EPHA3 107
EPHA4 108
EPHA5 97
EPHA7 100
EPHA8 118
EPHB1 109
EPHB2 95
EPHB3 96
EPHB4 123
ERBB2 97
ERBB4 97
ERK2 87
FAK fl 104
FER 103
FES 108
FGF-R1 107
FGF-R1 VM 93
FGF-R2 109
FGF-R3 100
FGF-R4 103
FGR 110
FLT3 D835Y 97
FLT3 wt 92
FRK 103
FYN 112
GRK2 107
GRK3 103
GRK4 100
GRK5 98
GRK6 87
GSK3-α 99
GSK3-β 91
HCK 112
HIPK1 88
HIPK3 141
HRI 102
IGF1-R 120
IKK-α 91
IKK-β 104
IKK-ɛ 103
INS-R 99
INSRR 95
IRAK1 92
IRAK4 111
ITK 107
JAK2 100
JAK3 97
JNK1 114
JNK2 109
JNK3 111
KIT wt 106
LCK 91
LIMK1 94
LTK 114
LYN 101
MAP4K4 90
MAPKAPK3 106
MAPKAPK5 94
MARK1 99
MARK2 89
MARK3 108
MATK 123
MEK1 wt 92
MELK 103
MERTK 102
MET 103
MINK1 105
MKK6 S207D/T211D 91
MST1 115
MST2 95
MST3 93
MST4 108
MUSK 101
MYLK2 99
Table W2. (continued )
NEK1 121
NEK11 102
NEK2 102
NEK3 119
NEK6 100
NEK7 111
NIK 93
NLK 106
p38-α 121
p38-β 123
p38-γ 105
PAK1 106
PAK2 103
PAK3 101
PAK4 97
PAK6 113
PAK7 96
PASK 87
PBK 109
PCTAIRE1 108
PDGFR-α 100
PDGFR-β 95
PDK1 105
PHKG2 108
PIM1 104
PIM2 88
PKA 101
PKC-α 102
PKC-β1 104
PKC-β2 81
PKC-δ 82
PKC-ɛ 114
PKC-η 101
PKC-γ 98
PKC-ι 106
PKC-μ 93
PKC-ν 92
PKC-θ 107
PKC-ζ 101
PLK1 95
PLK3 107
PRK1 104
PRK2 104
PRKD2 123
PRKG1 108
PRKG2 103
PRKX 112
PYK2 111
RAF1 Y340D/Y341D 99
RET 103
RIPK2 108
ROCK1 96
ROCK2 96
RON 98
ROS 100
RPS6KA1 89
RPS6KA2 105
RPS6KA3 108
RPS6KA4 93
RPS6KA5 118
RPS6KA6 99
S6K 105
S6K-β 105
SAK 86
SGK1 109
SGK2 100
SGK3 109
SNARK 96
SNF1LK2 109
SNK 105
SRC 99
SRPK1 97
SRPK2 87
STK17A 78
STK23 106
Table W2. (continued )
STK33 107
SYK 99
TAOK2 122
TBK1 99
TEC 104
TGFB-R1 100
TIE2 99
TRK-A 110
TRK-B 102
TRK-C 133
TSF1 97
TSK2 97
TSSK1 91
TTK 104
TYK2 92
TYRO3 116
VEGF-R1 116
VEGF-R2 112
VEGF-R3 99
VRK1 106
WEE1 99
WNK2 109
WNK3 101
YES 114
ZAP70 107
The detailed description of the kinase assay is provided in Table W1 and its legend.
In the current table, a residual activity of 120% means that 100 nM JLK1486 increases by 20%
the kinase activity compared to the control.
Table W3. Virtual Screening of Three Isoforms with Vina Software.
PPAR Isoform
Compounds*
JLK1486 Rosiglitazone Troglitazone
α −8.60 −8.30 −10.00
δ −11.90 −9.00 −10.10
γ −10.00 −9.10 −9.80
*Each result is the mean of the best result of five independent docking experiments, in kilocalories
per mole as obtained with the Vina scoring function.
